Archive:

Dec 24, 2025, 12:00 AM

Phase 3 randomized clinical trial: Both radiotherapy and imiquimod are efficient and well-tolerated treatments for lentigo maligna

Background: For patients with lentigo maligna who are not suitable for surgery, radiotherapy, or topical imiquimod are alternative nonsurgical treatments. Objective: This trial aimed to assess the ef…

Read more about 'Phase 3 randomized clinical trial: Both radiotherapy and imiquimod are efficient and well-tolerated treatments for lentigo maligna'...


Presence of white scales and keratin might guide accurate recognition of invasive SCC

Background: In people with lighter skin phototypes, squamous cell carcinoma (SCC) is typically nonpigmented and must be distinguished from other nonpigmented tumours. Although the dermoscopic features…

Read more about 'Presence of white scales and keratin might guide accurate recognition of invasive SCC'...


BO-112 plus pembrolizumab for patients with anti–PD-1–resistant advanced melanoma: Phase II clinical trial SPOTLIGHT-203

Purpose: Patients with anti–PD-1–resistant melanoma (MEL) have no well-defined standard of care. BO-112 is a synthetic, double-stranded RNA (poly I:C) nanoplexed with polyethylenimine that when admini…

Read more about 'BO-112 plus pembrolizumab for patients with anti–PD-1–resistant advanced melanoma: Phase II clinical trial SPOTLIGHT-203'...


Cumulative lifetime UVA exposure may be an underappreciated contributor to BCC and SCC risk

Background: Few epidemiological studies have distinguished the effects of solar ultraviolet (UV) radiation (UVR) wavelength, including UVB and UVA, on the risk of basal cell carcinoma (BCC) and squamo…

Read more about 'Cumulative lifetime UVA exposure may be an underappreciated contributor to BCC and SCC risk'...


Long-term follow-up of real-world adjuvant anti–PD-1 checkpoint inhibition and targeted therapy in patients with stage III melanoma

Purpose: Adjuvant treatment with immune checkpoint inhibition (PD-1) and targeted therapy (TT) with BRAF + MEK inhibitors significantly improved recurrence-free survival (RFS) of patients with stage I…

Read more about 'Long-term follow-up of real-world adjuvant anti–PD-1 checkpoint inhibition and targeted therapy in patients with stage III melanoma'...


Halving of Australian children’s naevus counts during 1992–2016 and change in sun behaviour

Background: The lifetime risk of cutaneous melanoma in Australia is the highest in the world. The most important melanoma risk factor is the number of acquired cutaneous melanocytic naevi (AMN) on a p…

Read more about 'Halving of Australian children’s naevus counts during 1992–2016 and change in sun behaviour'...


Incidence and associated risk factors of skin cancers in renal transplant recipients in Canterbury

Background: Skin cancer is a significant complication amongst renal transplant recipients, associated with substantial morbidity and mortality. Aim: This retrospective observational study aimed to as…

Read more about 'Incidence and associated risk factors of skin cancers in renal transplant recipients in Canterbury'...